PT - JOURNAL ARTICLE AU - Ackerson, Bradley K. AU - Bruxvoort, Katia J. AU - Qian, Lei AU - Sy, Lina S. AU - Qiu, Sijia AU - Tubert, Julia E. AU - Lee, Gina S. AU - Ku, Jennifer H. AU - Florea, Ana AU - Luo, Yi AU - Bathala, Radha AU - Stern, Julie AU - Choi, Soon K. AU - Takhar, Harpreet S. AU - Aragones, Michael AU - Marks, Morgan A. AU - Anderson, Evan J. AU - Zhou, Cindy Ke AU - Sun, Tianyu AU - Talarico, Carla A. AU - Tseng, Hung Fu TI - Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages AID - 10.1101/2023.12.11.23299663 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.11.23299663 4099 - http://medrxiv.org/content/early/2023/12/11/2023.12.11.23299663.short 4100 - http://medrxiv.org/content/early/2023/12/11/2023.12.11.23299663.full AB - Background Emerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received COVID-19 vaccine for >1 year. Assessment of long-term effectiveness of bivalent COVID-19 vaccines against circulating sublineages is important to inform the potential need for vaccination with updated vaccines.Methods In this test-negative study at Kaiser Permanente Southern California, sequencing-confirmed BA.4/BA.5- or XBB-related SARS-CoV-2-positive cases during 9/1/2022-6/30/2023 were matched 1:3 to SARS-CoV-2-negative controls. We assessed mRNA-1273 bivalent relative (rVE) and absolute vaccine effectiveness (VE) compared to ≥2 or 0 doses of original monovalent vaccine, respectively. Outcomes were BA.4/BA.5- or XBB-related infection, emergency department/urgent care (ED/UC) encounters, and hospitalization.Results The rVE analysis included 20,966 cases and 62,898 controls. rVE (95%CI) against BA.4/BA.5 at 14-60 days and 121-180 days was 52.7% (46.9-57.8%) and 35.5% (-2.8%-59.5%) for infection, and 59.3% (49.7-67.0%) and 33.2% (-28.2-68.0%) for ED/UC encounters. For BA.4/BA.5-related hospitalizations, rVE was 71.3% (44.9-85.1%) and 52.0% (-1.2-77.3%) at 14-60 days and 61-120 days, respectively. rVE against XBB at 14-60 days and 121-180 days, was 48.8% (33.4-60.7%) and -3.9% (-18.1-11.3%) for infection, 70.7% (52.4-82.0%) and 15.7% (-6.0-33.2%) for ED/UC encounters, and 87.9% (43.8-97.4%) and 57.1% (17.0-77.8%) for hospitalization. Results for VE and subgroup analyses (age, immunocompromise, and previous SARS-CoV-2 infection) were similar to rVE analyses.Conclusions rVE of mRNA-1273 bivalent vaccine against BA.4/BA.5 and XBB infections, ED/UC encounters, and hospitalizations waned over time. Periodic adjustment of vaccines to target emerging variants and revaccination may be important in reducing COVID-19 morbidity and mortality.Summary mRNA-1273 BA.4/BA.5 bivalent vaccine effectiveness against infection and hospitalization with BA.4/BA.5-related and XBB-related sublineages waned over time. Periodic vaccination with vaccines reflecting circulating variants may reduce SARS-CoV-2 associated morbidity and mortality.Competing Interest StatementBKA, LQ, LSS, SQ, JET, GSL, JHK, YL, RB, JS, SKC, HST, MA, and HFT are employees of Kaiser Permanente Southern California, which has been contracted by Moderna, Inc. to conduct this study. KJB is an adjunct investigator at Kaiser Permanente Southern California. AF was an employee of Kaiser Permanente Southern California; AF is currently an employee of SimulStat. MAM, EJA, CKZ, and TS are employees of and shareholders in Moderna, Inc. CAT was an employee of and a shareholder in Moderna Inc at the time of protocol development; CAT is currently an employee of AstraZeneca. BKA received funding from GlaxoSmithKline, Dynavax, Genentech, and Moderna unrelated to this manuscript. LQ received funding from GlaxoSmithKline, Dynavax, and Moderna unrelated to this manuscript. LSS received funding from GlaxoSmithKline, Dynavax, and Moderna unrelated to this manuscript. SQ received funding from Dynavax unrelated to this manuscript. JET received funding from Pfizer and Moderna unrelated to this manuscript. GSL received funding from GlaxoSmithKline and Moderna unrelated to this manuscript. JHK received funding from GlaxoSmithKline and Moderna unrelated to this manuscript. AF received funding from Pfizer, GlaxoSmithKline, Gilead, and Moderna unrelated to this manuscript. YL received funding from GlaxoSmithKline, Pfizer, and Moderna unrelated to this manuscript. RB received funding from GlaxoSmithKline unrelated to this manuscript. JS received funding from Pfizer, Sanofi, and Intercept unrelated to this manuscript. SKC received funding from Pfizer, Bayer AG, and Pancreatic Cancer Action Network unrelated to this manuscript. HST received funding from GlaxoSmithKline, Pfizer, ALK, and Wellcome unrelated to this manuscript. MA received funding from Pfizer unrelated to this manuscript. HFT received funding from GlaxoSmithKline and Moderna unrelated to this manuscript; HFT also served on advisory boards for Janssen and Pfizer.Funding StatementThis work was supported by Moderna, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Kaiser Permanente Southern California Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual-level data reported in this study involving human research participants are not publicly shared due to potentially identifying or sensitive patient information. Upon request to corresponding author [BKA], and subject to review and approval of an analysis proposal, KPSC may provide the deidentified aggregate-level data that support the findings of this study within 6 months. Anonymized data (deidentified data including participant data as applicable) that support the findings of this study may be made available from the investigative team in the following conditions: (1) agreement to collaborate with the study team on all publications, (2) provision of external funding for administrative and investigator time necessary for this collaboration, (3) demonstration that the external investigative team is qualified and has documented evidence of training for human subjects protections, and (4) agreement to abide by the terms outlined in data use agreements between institutions.